Gsk (GLAXF) Divestments (2009 - 2026)

Gsk's Divestments history runs 18 years deep, the most recent figure standing at $330.3 million for Q1 2026.

• In Q1 2026, Divestments rose 26324.98% year-over-year to $330.3 million; the TTM figure through Mar 2026 stood at $317.5 million (up 487.09% YoY), while the FY2025 annual figure was -$35.6 million, down 54.72% from the prior year.
• Divestments was $330.3 million for Q1 2026 at Gsk, up from $1.3 million in the prior quarter.
• In the past five years, Divestments ranged from a high of $330.3 million in Q1 2026 to a low of -$14.1 million in Q4 2022.
• Historically, Divestments has averaged $40.6 million across 5 years, with a median of -$1.3 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Divestments plunged 643.51% in 2023, then soared 26324.98% in 2026.
• A 5-year view of Divestments shows it stood at -$14.1 million in 2022, then soared by 611.45% to $72.0 million in 2023, then sank by 117.83% to -$12.8 million in 2024, then jumped by 110.36% to $1.3 million in 2025, then soared by 24731.76% to $330.3 million in 2026.
• The last three Divestments figures came in at $330.3 million (Q1 2026), $1.3 million (Q4 2025), and -$1.3 million (Q1 2025), per Business Quant data.